— · ₹988 · —
“Broker Consensus” is CAPITA1's algorithmic verdict from GMP, subscription, fundamentals & valuation — broker recommendations aren't in our data feed. GMP is an unofficial grey-market estimate. Not investment advice.
| Company | Market Cap | P/E | P/B | ROE | ROCE |
|---|---|---|---|---|---|
| Symbiotec Pharmalab (this IPO) | Not Available | 51.73x | 5.35x | 11.19% | 11.56% |
Cheapest by P/E: Symbiotec Pharmalab (51.7x) · Most expensive: Symbiotec Pharmalab (51.7x)
Company financials (EPS, NAV, ratios) from Issuer DRHP figures, compiled from public IPO listings; listed-peer market data from Yahoo Finance. Ratios computed at the upper price band; not investment advice.
Not available.
No exchange publishes a grey-market premium; this is not investment advice.
Bidding not started.
Not Available
Market data: Announced issue — not yet on the NSE calendar · updated 19 Aug 2026, 07:16 am
Fundamentals: Issuer DRHP figures, compiled from public IPO listings · fetched 19 Aug 2026, 07:16 am
IPO calendar, issue details and subscription from NSE. Any grey-market premium shown is CAPITA1’s own unofficial estimate, entered by hand — not investment advice, and no exchange publishes one. Company fundamentals (financials, peers) are not part of the live feed.